Communiqués MIRA Pharmaceuticals, Inc. Deutsche Boerse AG

Actions

K6S

US60458C1045

Recherche biotechnologique et médicale

Temps Différé Deutsche Boerse AG 15:25:01 02/10/2026			Varia. 5j.	Varia. 1 janv.
0,6445 ^PTS	-13,14%		-0,20%	-38,17%

18/09	MIRA Pharmaceuticals, Inc. : Maxim toujours positif	ZM
17/09	MIRA Pharmaceuticals, Inc. fait progresser le Ketamir-2 en phase 2a pour le traitement de la neuropathie périphérique induite par la chimiothérapie	CI

Communiqués

17/09	MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review	GL
01/09	MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND	GL
06/08	MIRA Reports Positive 7-Day Dog Study Results for SKNY-1	GL
30/07	MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies	GL
10/07	MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain	AQ
06/07	MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction	AQ
25/06	MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC	AQ
17/06	MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy	AQ
04/06	MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1	AQ
27/05	MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN	AQ
14/05	MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2	AQ
13/05	MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate	AQ
07/04	MIRA Pharmaceuticals : Investor Presentation	PU
23/03	MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies	AQ
19/06/25	MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology	AQ
08/05/25	MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review	AQ
06/05/25	MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity	AQ
23/04/25	MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation	AQ
16/04/25	MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion	AQ
01/04/25	MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain	AQ
25/03/25	MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development	AQ
24/03/25	MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development	AQ
13/03/25	MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain	AQ
11/12/24	MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile with No Adverse Findings, Paving the Way for IND Submission by Year-End	AQ
29/10/24	MIRA Pharmaceuticals Ketamir-2 Shows 60% Greater Efficacy than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain	AQ